Last reviewed · How we verify
NCT04558944
The Effect of Extracorporeal Shock Wave Therapy in the Treatment of Post Burn Scars
NA trial testing Extracorporal Shock Wave Therapy in Cicatrix, Hypertrophic in 40 participants. Completed in 15 February 2019.
15 February 2019
Quick facts
| Lead sponsor | Hospital Universitari Vall d'Hebron Research Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 January 2017 |
| Primary completion | 15 February 2019 |
| Estimated completion | 15 February 2019 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Extracorporal Shock Wave Therapy
Conditions studied
- Cicatrix, Hypertrophic — all drugs for Cicatrix, Hypertrophic →
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Who can join
18 and older, any sex, with Cicatrix, Hypertrophic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, randomized, controlled study. The patients were divided into two groups with twenty patients per group. The control group received the standard treatment for postburn scars. The treatment group received the standard treatment and treatment of postburn scars with Extracorporeal Shock Wave Therapy 512 impulses of 0.15mJ/mm 2 in each session, twice per week for 4 weeks. The investigators assessed the appearance of scar with the Vancouver Scar Scale (VSS), pruritus and pain with Visual Analog Scale (VAS) before the start of the treatment and at 2 weeks and 5 months after the treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04558944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cicatrix, Hypertrophic
Currently open trials in the same condition.
- NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting
Other Hospital Universitari Vall d'Hebron Research Institute trials
Trials by the same sponsor.
- NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
- NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
- NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
- NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
- NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04558944 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
- Last refreshed: 1 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04558944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing